The delisting notice is a procedural step tied to the pending merger — the real binary catalyst is the merger closing. Monitor shareholder vote and S-4 effectiveness for the merger timeline. If the merger fails or is delayed past March 2027, delisting risk becomes acute.
Price Chart
Executive Summary
InMed Pharmaceuticals received a Nasdaq deficiency notice for failing to meet the minimum $2.5M shareholders' equity requirement, reporting only $1,075,007 in its FY2026 10-K. The company attributes the shortfall largely to merger-related expenses and expects to regain compliance upon closing its merger with Mentari Therapeutics, which is projected to bring ~$490M in gross proceeds. The delisting risk is contingent on the merger closing in Q4 2026, but failure to close or regain compliance could result in delisting.
Key Facts
- Nasdaq notified InMed on Sept 16, 2026 of non-compliance with Listing Rule 5550(b)(1) requiring $2.5M minimum shareholders' equity.
- InMed reported shareholders' equity of $1,075,007 in its FY2026 10-K, well below the $2.5M threshold.
- The company has 45 days (until Nov 2, 2026) to submit a compliance plan; if accepted, Nasdaq may grant up to 180 days (until Mar 15, 2027) to regain compliance.
- The decline in equity is attributed to transaction costs from the pending merger with Mentari Therapeutics, wind-down of BayMedica, impairment charges, and operating losses.
- Post-merger, the combined company expects ~$490M in gross proceeds from Mentari's pre-closing financing, which InMed believes will restore compliance.
- The merger is expected to close in Q4 2026, subject to shareholder approval.
- InMed's stock price has risen ~99.8% since the merger announcement, per the filing.
Financial Impact
Shareholders' equity of $1,075,007 vs. $2,500,000 minimum; potential delisting risk if merger fails to close. Post-merger expected proceeds of ~$490M would resolve the deficiency.
Risk Factors
- Merger may not close on expected timeline or at all, leaving InMed unable to regain compliance.
- Nasdaq may reject the compliance plan, triggering delisting proceedings.
- Even if the merger closes, the combined entity must maintain ongoing listing requirements.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-101492 |
| Document: ea030576901ex99-1.htm | 0001213900-26-101492 |
| Document: 0001213900-26-101492-index-headers.html | 0001213900-26-101492 |
| Document: 0001213900-26-101492-index.html | 0001213900-26-101492 |
| Document: 0001213900-26-101492.txt | 0001213900-26-101492 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 18d ago | SC 13G/A | $1.33 | awaiting T+20 | — | $1.58 (+18.80%) |
Oct 2, 2026 24d ago | EFFECT | $1.33 | awaiting T+20 | — | $1.58 (+18.80%) |
Sep 18, 2026 5w ago | 8-K | $1.38 $1.37 | ▲ +1.06% | ▲ +0.15% | $1.58 (−14.49%) |
Sep 9, 2026 6w ago | 425 | $1.31 $1.33 | ▲ +1.53% | ▼ −0.60% | $1.58 (+20.61%) |
Jul 10, 2026 15w ago | 8-K | $1.57 $1.41 | ▲ +10.19% | ▲ +13.38% | $1.58 (−0.64%) |
Jul 2, 2026 16w ago | S-4 | $1.56 $1.50 | ▲ +3.85% | ▲ +3.43% | $1.58 (−1.28%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.58 $1.66 | ▲ +5.06% | ▲ +3.17% | $1.58 (+0.00%) |
Jun 10, 2026 19w ago | 8-K | $1.51 $1.66 | ▲ +9.93% | ▲ +6.31% | $1.58 (+4.64%) |
May 19, 2026 22w ago | 425 | $1.60 $1.49 | ▼ −6.88% | ▼ −7.86% | $1.58 (−1.25%) |
May 19, 2026 22w ago | 8-K | $1.60 $1.49 | ▼ −6.88% | ▼ −7.86% | $1.58 (−1.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers